ZYMEWORKS INC. Increase (Decrease) in Accounts Receivable
ZYMEWORKS INC. (ZYME) reported Increase (Decrease) in Accounts Receivable of $1.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- ZYMEWORKS INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $1.26M.
- ZYMEWORKS INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $36.00K.
- ZYMEWORKS INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$24.71M, a 178.13% decline year-over-year.
- ZYMEWORKS INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $26.72M.
- ZYMEWORKS INC. increase (decrease) in accounts receivable for fiscal 2025 was -$51.20M, a 240.82% decline from fiscal 2024.
- ZYMEWORKS INC. increase (decrease) in accounts receivable for fiscal 2024 was $36.36M.
- ZYMEWORKS INC. increase (decrease) in accounts receivable for fiscal 2023 was -$13.92M, a 179.51% decline from fiscal 2022.
- ZYMEWORKS INC. increase (decrease) in accounts receivable for fiscal 2022 was $17.51M, a 6482.33% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.29M 10-Q · filed 2026-08-06 | -$23.42M derived: sum of 3 quarters · filed 2026-08-06 | $3.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $36.00K 10-Q · filed 2026-05-07 | -$24.68M derived: sum of 2 quarters · filed 2026-05-07 | $2.04M derived: sum of 3 quarters · filed 2026-05-07 | -$19.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$24.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.01M derived: sum of 2 quarters · filed 2026-03-02 | -$19.98M derived: sum of 3 quarters · filed 2026-08-06 | -$51.20M 10-K · filed 2026-03-02 |
| 2025-09-30 | $26.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.73M derived: sum of 2 quarters · filed 2026-08-06 | -$26.49M 10-Q · filed 2025-11-06 | $5.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$21.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$53.21M 10-Q · filed 2026-08-06 | -$21.58M derived: sum of 3 quarters · filed 2026-08-06 | -$29.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$31.22M 10-Q · filed 2026-05-07 | $411.00K derived: sum of 2 quarters · filed 2026-05-07 | -$7.47M derived: sum of 3 quarters · filed 2026-05-07 | -$6.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $31.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $23.75M derived: sum of 2 quarters · filed 2026-03-02 | $24.89M derived: sum of 3 quarters · filed 2026-03-02 | $36.36M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$7.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$6.74M derived: sum of 2 quarters · filed 2025-11-06 | $4.73M 10-Q · filed 2025-11-06 | -$43.07M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $12.61M 10-Q · filed 2025-08-07 | -$35.19M derived: sum of 3 quarters · filed 2026-03-02 | -$16.73M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $11.47M 10-Q · filed 2025-05-08 | -$36.33M derived: sum of 2 quarters · filed 2026-03-02 | -$17.87M derived: sum of 3 quarters · filed 2026-03-02 | -$35.97M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$47.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$29.34M derived: sum of 2 quarters · filed 2026-03-02 | -$47.44M derived: sum of 3 quarters · filed 2026-03-02 | -$13.92M 10-K · filed 2026-03-02 |
| 2023-09-30 | $18.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $357.00K derived: sum of 2 quarters · filed 2024-10-31 | $33.87M 10-Q · filed 2024-10-31 | $60.55M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | -$18.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $15.42M 10-Q · filed 2024-08-01 | $42.09M derived: sum of 3 quarters · filed 2025-03-05 | $44.40M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $33.52M 10-Q · filed 2024-05-02 | $60.19M derived: sum of 2 quarters · filed 2025-03-05 | $62.50M derived: sum of 3 quarters · filed 2025-03-05 | $62.35M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $26.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $28.98M derived: sum of 2 quarters · filed 2025-03-05 | $28.83M derived: sum of 3 quarters · filed 2025-03-05 | $17.51M 10-K · filed 2025-03-05 |
| 2022-09-30 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.16M derived: sum of 2 quarters · filed 2023-11-07 | -$9.16M 10-Q · filed 2023-11-07 | $1.52M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$11.48M 10-Q · filed 2023-08-10 | -$789.00K derived: sum of 3 quarters · filed 2024-03-06 | |
| 2022-03-31 | -$11.32M 10-Q · filed 2023-05-08 | -$638.00K derived: sum of 2 quarters · filed 2024-03-06 | ||
| 2021-12-31 | $10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $266.00K 10-K · filed 2024-03-06 | ||
| 2021-09-30 | -$10.42M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $13.11M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |